Paper
23 February 2011 Laser immunotherapy for the treatment of human breast cancer: one-year follow up results
Tomas Hode, Orn Adalsteinsson, Gabriela L. Ferrel, John A. Lunn, Maria C. Guerra, Xiaosong Li, Robert E. Nordquist, Wei R. Chen
Author Affiliations +
Proceedings Volume 7900, Biophotonics and Immune Responses VI; 790009 (2011) https://doi.org/10.1117/12.874798
Event: SPIE BiOS, 2011, San Francisco, California, United States
Abstract
The immediate goal of the trial was to determine the breast cancer patient tolerance and the toxicity of Laser immunotherapy (LIT), the optimal dose for the alteration of the course of the disease, and the reduction of the tumor burden. Ten stage III and IV cancer patients were treated, all of which were considered to be out of all other options. No toxicity or significant adverse reactions were observed and the treatment was well tolerated by all patients. Almost all the treated patients have had positive responses: A majority of patients experienced large-scale reduction of primary breast tumors, and all the stage IV patients experienced either complete or significant reductions in distant metastases in the lungs, liver, bone, and the brain, indicating a strong systemic effect of the treatment. We also report two cases of triple negative breast cancer patients that showed limited or no response to LIT.
© (2011) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Tomas Hode, Orn Adalsteinsson, Gabriela L. Ferrel, John A. Lunn, Maria C. Guerra, Xiaosong Li, Robert E. Nordquist, and Wei R. Chen "Laser immunotherapy for the treatment of human breast cancer: one-year follow up results", Proc. SPIE 7900, Biophotonics and Immune Responses VI, 790009 (23 February 2011); https://doi.org/10.1117/12.874798
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Tumors

Breast cancer

Cancer

Toxicity

Lung

Breast

Oncology

Back to Top